<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67958">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02221154</url>
  </required_header>
  <id_info>
    <org_study_id>CHD 096-13</org_study_id>
    <nct_id>NCT02221154</nct_id>
  </id_info>
  <brief_title>Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF)</brief_title>
  <acronym>FIV-INOPK</acronym>
  <official_title>Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The original mechanism of action of myo-inositol and preliminary results available in the
      literature on its use in IVF suggest its value as adjuvant gonadotropin therapy to reduce
      the risk of OHSS in PCOS patients.

      The aim of the study is to demonstrate that administration of myo-inositol decreases the
      incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk infertile with PCOS
      supported in IVF patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of OHSS in each group, graded mild, moderate or severe based on the recommendations</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Inofolic®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard ovarian stimulation and Inofolic®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonadotropins;Folic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard ovarian stimulation without Inofolic®</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inofolic®</intervention_name>
    <arm_group_label>Inofolic®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gonadotropins; Folic Acid</intervention_name>
    <description>standard ovarian stimulation</description>
    <arm_group_label>Inofolic®</arm_group_label>
    <arm_group_label>Gonadotropins;Folic Acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients PCOS (Rotterdam ESHRE / ASRM criteria)

        Combination of at least two of the following three criteria:

          -  Cycle disorder

          -  Clinical hyperandrogenism and / or biological

          -  Account antral follicles&gt; 24

          -  Age ≤ 18 ≤ 38 years

          -  BMI &lt;35 kg / m²

          -  Able to understand the protocol and signed informed consent

        Exclusion Criteria:

          -  Patients not having the Rotterdam criteria

          -  Patients&gt; 38 years and / or BMI&gt; 35 kg / m²

          -  Woman enjoying a measure of legal protection

          -  Hypersensitivity to any component of the Inofolic (myo-inositol, soy, folic acid,
             glycerol, gelatin, coloring E171)

          -  Participation in another interventional biomedical research with treatment
             administered may disrupt ovarian stimulation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabienne DELAY, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD Vendée La Roche sur Yon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucie AUZANNEAU, ARC</last_name>
    <email>lucie.auzanneau@chd-vendee.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHI de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nathalie MASSIN, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabienne DELAY, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul BARRIERE, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Saint Nazaire</name>
      <address>
        <city>Saint Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Julien BANCQUART, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 25, 2016</lastchanged_date>
  <firstreceived_date>August 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>in vitro fertilization</keyword>
  <keyword>ovarian hyperstimulation</keyword>
  <keyword>pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inositol</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
